Articles From: Retired Brig. Gen. Richard S. Stapp Appointed Vice President of Technology Development for Northrop Grumman Aerospace Systems to Revenge of the nerd: Zuckerberg on why he wears the grey T-shirt


2011/04/28
The risks of holding too much in employer stock don't end when you retire.
Sign-up for Retirees and Pre-Retirees: Lighten Up on Company Stock investment picks
2012/03/22
Bad timing could obliterate the long-term benefits of these investments.
Sign-up for Retirees: Look Before You Leap Into Commodities investment picks
2015/01/18
Younger investors may want options for accessing their funds prior to retirement.
Sign-up for Retirement Plans for Young People: Know Your Choices investment picks
2014/12/22
As part of its new digital experience for participants, the Principal Financial Group ® has introduced an interactive Retirement Wellness Planner to help users easily manage, visualize and plan for their retirement savings goals.
Sign-up for Retirement Wellness Planner from The Principal Helps Participants Visualize Goals investment picks
By Tess Stynes Retractable Technologies Inc. (RVP) said it would recover $340.5 million from medical-product maker Becton Dickinson & Co.
Sign-up for Retractable Tech to Get $340.5 Million From Becton Dickinson investment picks
By Tess Stynes Retractable Technologies Inc. (RVP) said it would recover $340.5 million from medical-product maker Becton Dickinson & Co.
Sign-up for Retractable Tech to Get $340.5 Million From Becton Dickinson--Update investment picks
2015/1/12
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0987006003&sourceType=1 http://media3.marketwire.com/logos/20130429-FISUR%20LARGE.jpg KELOWNA, BRITISH COLUMBIA --
Sign-up for RETRANSMISSION: Fission's Initial Resource Totals at PLS: 79.6M lbs Indicated and 25.9M lbs Inferred investment picks
Retrophin, Inc. (NASDAQ:RTRX) and Asklepion Pharmaceuticals, LLC, a privately held rare disease pharmaceutical development company, today announced the signing of a definitive agreement under which Retrophin has acquired the exclusive right to purchase from Asklepion, all worldwide rights, titles, and ownership of cholic acid for the treatment of bile acid synthesis defects, if approved by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, Retrophin will pay Asklepion an upfront payment of $5 million and up to $73 million in milestones based on approval and net product sales, plus tiered royalties on future net sales of cholic acid.
Sign-up for Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion Pharmaceuticals investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to market open on Monday, December 22, 2014.
Sign-up for Retrophin Announces Addition to the NASDAQ Biotechnology Index investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced that the Board of Directors has appointed Stephen Aselage as Chief Executive Officer (CEO), effective immediately.
Sign-up for Retrophin Announces Appointment of Stephen Aselage as Chief Executive Officer investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Laura M.
Sign-up for Retrophin Names Laura M. Clague as Chief Financial Officer investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Margaret Valeur-Jensen, Ph.D. to the newly created position of General Counsel, effective immediately.
Sign-up for Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary, unaudited financial data, the Company expects net product revenue for the fiscal year ended December 31, 2014 of approximately $28.3 million.
Sign-up for Retrophin Provides Corporate Update investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced the grant of inducement awards to 14 employees that occurred on January 5, 2015.
Sign-up for Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) investment picks
Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the quarter ended September 30, 2014.
Sign-up for Retrophin Reports Third Quarter 2014 Financial Results investment picks
2014/11/7
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a class action lawsuit has been filed against Retrophin, Inc. (“Retrophin” or “Company”) (NasdaqGM: RTRX) and several officers and directors for acts taken during the period of March 27, 2014 to September 30, 2014 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Retrophin.
Sign-up for Retrophin Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
Retrophin, Inc. (NASDAQ:RTRX) today announced that it will report its third quarter financial results on Thursday, November 13, 2014 after the close of the U.S. financial markets.
Sign-up for Retrophin to Report Third Quarter 2014 Financial Results investment picks
2014/12/11
The New Jersey home renovation of Joseph Simmons—best known as Rev Run from the iconic rap group, RUN DMC—continues in the second season of DIY Network’s popular Rev Run’s Renovation .
Sign-up for Rev Run Returns for Season Two of His DIY Network Hit Series ‘Rev Run’s Renovation’ on January 3 investment picks
NEWARK, Calif., Dec.
Sign-up for Revance Therapeutics Added to NASDAQ Biotechnology Index investment picks
RT002 Achieved Median Duration of 7 Months NEWARK, Calif., Jan.
Sign-up for Revance Therapeutics Announces Publication of Positive Results From RT002 Phase 1/2 Study investment picks
Specifies Milestones for Botulinum Toxin Product Candidates, Topical RT001 and Injectable RT002, for Aesthetic and Therapeutic Indications NEWARK, Calif., Jan.
Sign-up for Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015 investment picks
– Confirmation of Plans to Initiate Phase 2 Active Comparator Study for RT002 in 2014 – NEWARK, Calif., Nov.
Sign-up for Revance Therapeutics Releases Third Quarter 2014 Results investment picks
2014/11/9
By Charles Passy, MarketWatch Don't criticize Mark Zuckerberg's fashion sense (or lack thereof). The Facebook founder says he's sporting those grey T-shirts only to help company shareholders realize greater profits.
Sign-up for Revenge of the nerd: Zuckerberg on why he wears the grey T-shirt investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Retired Brig. Gen. Richard S. Stapp Appointed Vice President of Technology Development for Northrop Grumman Aerospace Systems to Revenge of the nerd: Zuckerberg on why he wears the grey T-shirt
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent